| Title |
Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
|
|---|---|
| Published in |
OncoTargets and therapy, August 2022
|
| DOI | 10.2147/ott.s382501 |
| Pubmed ID | |
| Authors |
Enrique Pérez-Cárdenas, Lucía Taja-Chayeb, Catalina Trejo-Becerril, José Chanona-Vilchis, Alma Chávez-Blanco, Guadalupe Domínguez-Gómez, Elizabeth Langley, Alejandro García-Carrancá, Alfonso Dueñas-González |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2022.
All research outputs
#16,734,944
of 25,392,582 outputs
Outputs from OncoTargets and therapy
#986
of 3,016 outputs
Outputs of similar age
#235,797
of 431,954 outputs
Outputs of similar age from OncoTargets and therapy
#7
of 25 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,954 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.